CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
PectaSol-C Modified Citrus Pectin (MCP)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01681823
NCT01681823Phase 2Completed
CompareCT.gov

Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA

EcoNugenics·interventional·Posted Sep 10, 2012·Updated Jan 29, 2020

In Brief

A Phase 2 clinical trial evaluating PectaSol-C Modified Citrus Pectin (MCP) for Prostatic Neoplasms. Completed, enrolled 60 participants across 1 site.

Detailed Summary

To determine if the oral administration of PectaSol-C Modified Citrus Pectin (MCP) is effective at improving Prostate Specific Antigen (PSA) kinetics in men with biochemical relapsed prostate cancer and serial increases in PSA levels. Also, documentation of any side effects or benefits within parameter of the study is included.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasms
CountriesIsrael
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2012
Enrollment StartJun 1, 2013
Primary CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 13.8 years ago

Interventions

PectaSol-C Modified Citrus Pectin (MCP)dietary

Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).